APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle (Q36366147)

13 August 2017

1 reference

title

APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle (English)

1 reference

13 August 2017

Ya-Lin Chiu

1

1 reference

13 August 2017

Warner C Greene

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

30 December 2005

1 reference

Journal of Biological Chemistry

13 August 2017

published in

1 reference

13 August 2017

volume

281

1 reference

13 August 2017

issue

13

1 reference

13 August 2017

page(s)

8309-8312

1 reference

Evidence for a newly discovered cellular anti-HIV-1 phenotype

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Constitutive expression of AID leads to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The interaction between HIV-1 Gag and APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

DNA deamination mediates innate immunity to retroviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G targets specific virus species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Inhibition of hepatitis B virus replication by APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC-mediated interference with hepadnavirus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G targets human T-cell leukemia virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Complementary function of the two catalytic domains of APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Mobile elements: drivers of genome evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Rapid evolution of primate antiviral enzyme APOBEC3G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.R500021200

21 January 2018

Identifiers

DOI

10.1074/JBC.R500021200

1 reference

13 August 2017

1 reference